Review Article | Published:

Influence of Dietary Restriction on Irritable Bowel Syndrome

The American Journal of Gastroenterology (2018) | Download Citation

Subjects

Abstract

Up to two-thirds of patients with IBS attribute their gastrointestinal symptoms to food. The therapeutic focus of IBS has been to alleviate gastrointestinal symptoms, approached by pharmaceutical and non-pharmaceutical treatments. Although the most traditional approach has involved the use of medications such as bulking agents, anticholinergics, antispasmodics, and antidiarrheals, unfortunately these are only modestly effective and patients are left with a small menu of successful pharmacologic agents. These treatments, however, are not always enough to alleviate symptoms. Alternative approaches have therefore been tried, including dietary manipulation. This article aims to review dietary restrictions as a non-pharmaceutical management approach for IBS, covering literature on various dietary triggers and the impact of dietary manipulation on gastrointestinal symptoms.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71–80. https://doi.org/10.2147/CLEP.S40245

  2. 2.

    Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–21.e4. https://doi.org/10.1016/j.cgh.2012.02.029

  3. 3.

    Chang L. Updates to the rome criteria for irritable bowel syndrome. Gastroenterol Hepatol. 2017;13:304–6.

  4. 4.

    What’s New for Rome IV – Rome Foundation. https://theromefoundation.org/rome-iv/whats-new-for-rome-iv/. Accessed on 23 November 2017.

  5. 5.

    Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology . 2016;150:1393–07.e5. https://doi.org/10.1053/j.gastro.2016.02.031

  6. 6.

    Kibune Nagasako C, Garcia Montes C, Silva Lorena SL, Mesquita MA. Irritable bowel syndrome subtypes: Clinical and psychological features, body mass index and comorbidities. Rev Esp Enferm Dig. 2016;108:59–64. https://doi.org/10.17235/reed.2015.3979/2015

  7. 7.

    Nanayakkara WS, Skidmore PM, O’Brien L, Wilkinson TJ, Gearry RB. Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date. Clin Exp Gastroenterol. 2016;9:131–42. https://doi.org/10.2147/CEG.S86798

  8. 8.

    Villani A-C, Lemire M, Thabane M, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology . 2010;138:1502–13. https://doi.org/10.1053/j.gastro.2009.12.049

  9. 9.

    Klem F, Wadhwa A, Prokop LJ, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology . 2017;152:1042–54.e1. https://doi.org/10.1053/j.gastro.2016.12.039

  10. 10.

    Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg. 2012;25:46–52. https://doi.org/10.1055/s-0032-1301759

  11. 11.

    Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome–results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29:329–41. https://doi.org/10.1111/j.1365-2036.2008.03881.x

  12. 12.

    Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:1702–12. https://doi.org/10.1038/ajg.2012.254

  13. 13.

    Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32. https://doi.org/10.1056/NEJMoa1004409

  14. 14.

    Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology . 2016;151:1113–21. https://doi.org/10.1053/j.gastro.2016.08.003

  15. 15.

    Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374:242–53. https://doi.org/10.1056/NEJMoa1505180

  16. 16.

    Lewis JH. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Rev Gastroenterol Hepatol. 2010;4:13–29. https://doi.org/10.1586/egh.09.72

  17. 17.

    Andresen V, Hollerbach S. Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome? Drug Saf. 2004;27:283–92.

  18. 18.

    Gilkin RJ. The spectrum of irritable bowel syndrome: a clinical review. Clin Ther. 2005;27:1696–709. https://doi.org/10.1016/j.clinthera.2005.11.012

  19. 19.

    Böhn L, Störsrud S, Törnblom H, Bengtsson U, Simrén M. Self-reported food-related gastrointestinal symptoms in ibs are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol. 2013;108:634–41. https://doi.org/10.1038/ajg.2013.105

  20. 20.

    El-Salhy M, Gundersen D. Diet in irritable bowel syndrome. Nutr J. 2015;14:36 https://doi.org/10.1186/s12937-015-0022-3

  21. 21.

    Leonard MM, Sapone A, Catassi C, Fasano A. Celiac disease and nonceliac gluten sensitivity: a review. JAMA . 2017;318:647–56. https://doi.org/10.1001/jama.2017.9730

  22. 22.

    Makharia A, Catassi C, Makharia GK. The overlap between irritable bowel syndrome and non-celiac gluten sensitivity: a clinical dilemma. Nutrients . 2015;7:10417–26. https://doi.org/10.3390/nu7125541

  23. 23.

    Catassi C, Alaedini A, Bojarski C, et al. The overlapping area of non-celiac gluten sensitivity (ncgs) and wheat-sensitive irritable bowel syndrome (IBS): an update. Nutrients. 2017;9:pii: E1268. https://doi.org/10.3390/nu9111268

  24. 24.

    Giorgio RD, Volta U, Gibson PR. Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction? Gut . 2016;65:169–78. https://doi.org/10.1136/gutjnl-2015-309757

  25. 25.

    Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. 2011;106:508–14. https://doi.org/10.1038/ajg.2010.487. quiz515

  26. 26.

    Vazquez–Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology . 2013;144:903–11.e3. https://doi.org/10.1053/j.gastro.2013.01.049

  27. 27.

    Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology . 2013;145:320–28.e3. https://doi.org/10.1053/j.gastro.2013.04.051

  28. 28.

    Skodje GI, Sarna VK, Minelle IH, et al. Fructan, rather than gluten, induces symptoms in patients with self-reported non-celiac gluten sensitivity. Gastroenterology . 2017. https://doi.org/10.1053/j.gastro.2017.10.040

  29. 29.

    Gluten-free diet: What’s allowed, what’s not. Mayo Clinic. http://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/in-depth/gluten-free-diet/art-20048530. Accessed on 14 November 2017.

  30. 30.

    Saturni L, Ferretti G, Bacchetti T. The gluten-free diet: safety and nutritional quality. Nutrients . 2010;2:16–34. https://doi.org/10.3390/nu20100016

  31. 31.

    Frigolet M-E, Barragán V-ER, González MT. Low-carbohydrate diets: a matter of love or hate. Ann Nutr Metab. 2011;58:320–34. https://doi.org/10.1159/000331994

  32. 32.

    Paoli A. Ketogenic diet for obesity: friend or foe? Int J Environ Res Public Health. 2014;11:2092–107. https://doi.org/10.3390/ijerph110202092

  33. 33.

    Bueno NB, de Melo ISV, de Oliveira SL, da Rocha Ataide T. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr. 2013;110:1178–87. https://doi.org/10.1017/S0007114513000548

  34. 34.

    Austin GL, Dalton CB, Hu Y, et al. A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7:706–08.e1. https://doi.org/10.1016/j.cgh.2009.02.023

  35. 35.

    Goldstein R, Braverman D, Stankiewicz H. Carbohydrate malabsorption and the effect of dietary restriction on symptoms of irritable bowel syndrome and functional bowel complaints. Isr Med Assoc J. 2000;2:583–7.

  36. 36.

    Deng Y, Misselwitz B, Dai N, Fox M. Lactose intolerance in adults: biological mechanism and dietary management. Nutrients . 2015;7:8020–35. https://doi.org/10.3390/nu7095380

  37. 37.

    Misselwitz B, Pohl D, Frühauf H, Fried M, Vavricka SR, Fox M. Lactose malabsorption and intolerance: pathogenesis, diagnosis and treatment. United Eur. Gastroenterol J. 2013;1:151–9. https://doi.org/10.1177/2050640613484463

  38. 38.

    Bhatnagar S, Aggarwal R. Lactose intolerance. BMJ . 2007;334:1331–2. https://doi.org/10.1136/bmj.39252.524375.80

  39. 39.

    Farup PG, Monsbakken KW, Vandvik PO. Lactose malabsorption in a population with irritable bowel syndrome: prevalence and symptoms. A case‐control study. Scand J Gastroenterol. 2004;39:645–9. https://doi.org/10.1080/00365520410005405

  40. 40.

    Zheng X, Chu H, Cong Y, et al. Self-reported lactose intolerance in clinic patients with functional gastrointestinal symptoms: prevalence, risk factors, and impact on food choices. Neurogastroenterol Motil. 2015;27:1138–46. https://doi.org/10.1111/nmo.12602

  41. 41.

    Parker TJ, Woolner JT, Prevost AT, Tuffnell Q, Shorthouse M, Hunter JO. Irritable bowel syndrome: is the search for lactose intolerance justified? Eur J Gastroenterol Hepatol. 2001;13:219–25.

  42. 42.

    Vernia P, Ricciardi MR, Frandina C, Bilotta T, Frieri G. Lactose malabsorption and irritable bowel syndrome. Effect of a long-term lactose-free diet. Ital J Gastroenterol. 1995;27:117–21.

  43. 43.

    Böhmer CJ, Tuynman HA. The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: a 5-year follow-up study. Eur J Gastroenterol Hepatol. 2001;13:941–4.

  44. 44.

    Levitt M, Wilt T, Shaukat A. Clinical implications of lactose malabsorption versus lactose intolerance. J Clin Gastroenterol. 2013;47:471–80. https://doi.org/10.1097/MCG.0b013e3182889f0f

  45. 45.

    Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017;112:775–84. https://doi.org/10.1038/ajg.2017.46

  46. 46.

    Pimentel M, Kong Y, Park S. Breath testing to evaluate lactose intolerance in irritable bowel syndrome correlates with lactulose testing and may not reflect true lactose malabsorption. Am J Gastroenterol. 2003;98:2700–4. https://doi.org/10.1111/j.1572-0241.2003.08670.x

  47. 47.

    Barrett JS, Gearry RB, Muir JG, et al. Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther. 2010;31:874–82. https://doi.org/10.1111/j.1365-2036.2010.04237.x

  48. 48.

    S. Eswaran, (2017) Low FODMAP in 2017: Lessons learned from clinical trials and mechanistic studies. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2017;29(4). https://doi.org/10.1111/nmo.13055

  49. 49.

    Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010;25:1366–73. https://doi.org/10.1111/j.1440-1746.2010.06370.x

  50. 50.

    Barrett JS. How to institute the low-FODMAP diet. J Gastroenterol Hepatol. 2017;32(Suppl 1):8–10. https://doi.org/10.1111/jgh.13686

  51. 51.

    Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008;6:765–71. https://doi.org/10.1016/j.cgh.2008.02.058

  52. 52.

    Böhn L, Störsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology . 2015;149:1399–07.e2. https://doi.org/10.1053/j.gastro.2015.07.054

  53. 53.

    Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Am J Gastroenterol. 2016;111:1824–32. https://doi.org/10.1038/ajg.2016.434

  54. 54.

    Halmos EP. When the low FODMAP diet does not work. J Gastroenterol Hepatol. 32(S1):69–72. https://doi.org/10.1111/jgh.13701

  55. 55.

    Hustoft TN, Hausken T, Ystad SO, et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2017;29. https://doi.org/10.1111/nmo.12969

  56. 56.

    Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut . 2015;64:93–100. https://doi.org/10.1136/gutjnl-2014-307264

  57. 57.

    J Farida, E Shah, S Ball, et al. Micronutrient intake changes with the low FODMAP and mNICE Diets. In: World Congress of Gastroenterology; 2017.

  58. 58.

    Eswaran S. Low FODMAP in 2017: Lessons learned from clinical trials and mechanistic studies. Neurogastroenterol Motil. 2017;29. :https://doi.org/10.1111/nmo.13055

  59. 59.

    Lillywhite JM, Simonsen JE, Uchanski ME. Spicy pepper consumption and preferences in the United States. HortTechnology . 2013;23:868–76.

  60. 60.

    Esmaillzadeh A, Keshteli AH, Hajishafiee M, Feizi A, Feinle-Bisset C, Adibi P. Consumption of spicy foods and the prevalence of irritable bowel syndrome. World J Gastroenterol Wjg. 2013;19:6465–71. https://doi.org/10.3748/wjg.v19.i38.6465

  61. 61.

    Gonlachanvit S. Are Rice and Spicy Diet Good for Functional Gastrointestinal Disorders? J Neurogastroenterol Motil. 2010;16:131–8. https://doi.org/10.5056/jnm.2010.16.2.131

  62. 62.

    Gutierrez R, Simon SA. Why do people living in hot climates like their food spicy? Temp Multidiscip Biomed J. 2015;3:48–49. https://doi.org/10.1080/23328940.2015.1119616

  63. 63.

    Lv J, Qi L, Yu C, et al. Consumption of spicy foods and total and cause specific mortality: population based cohort study. BMJ . 2015;351:h3942 https://doi.org/10.1136/bmj.h3942

  64. 64.

    Akbar A, Yiangou Y, Facer P, Walters JRF, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut . 2008;57:923–9. https://doi.org/10.1136/gut.2007.138982

  65. 65.

    Gonlachanvit S, Mahayosnond A, Kullavanijaya P. Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral nociception hypersensitivity. Neurogastroenterol Motil J Eur Gastrointest Motil Soc. 2009;21:23–32. https://doi.org/10.1111/j.1365-2982.2008.01167.x

  66. 66.

    Bortolotti M, Porta S. Effect of red pepper on symptoms of irritable bowel syndrome: preliminary study. Dig Dis Sci. 2011;56:3288–95. https://doi.org/10.1007/s10620-011-1740-9

  67. 67.

    Fadus MC, Lau C, Bikhchandani J, Lynch HT. Curcumin: an age-old anti-inflammatory and anti-neoplastic agent. J Tradit Complement Med. 2017;7:339–46. https://doi.org/10.1016/j.jtcme.2016.08.002

  68. 68.

    Portincasa P, Bonfrate L, Scribano MLL, et al. Curcumin and fennel essential oil improve symptoms and quality of life in patients with irritable bowel syndrome. J Gastrointest Liver Dis. 2016;25:151–7.

  69. 69.

    Dulbecco P, Savarino V. Therapeutic potential of curcumin in digestive diseases. World J Gastroenterol Wjg. 2013;19:9256–70. https://doi.org/10.3748/wjg.v19.i48.9256

  70. 70.

    Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med. 2004;10:1015–8. https://doi.org/10.1089/acm.2004.10.1015

  71. 71.

    El-Salhy M, Ystad SO, Mazzawi T, Gundersen D. Dietary fiber in irritable bowel syndrome (Review). Int J Mol Med. 2017;40:607–13. https://doi.org/10.3892/ijmm.2017.3072

  72. 72.

    Zuckerman MJ. The role of fiber in the treatment of irritable bowel syndrome: therapeutic recommendations. J Clin Gastroenterol. 2006;40:104–8.

  73. 73.

    Manning AP, Harvey RF, Heaton KW, Uglow P. Wheat fibre and irritable bowel syndrome: a controlled trial. Lancet. 1977;310:417–8. https://doi.org/10.1016/S0140-6736(77)90605-5

  74. 74.

    Moayyedi P, Quigley EMM, Lacy BE, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:1367–74. https://doi.org/10.1038/ajg.2014.195

  75. 75.

    Cann PA, Read NW, Holdsworth CD. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut . 1984;25:168–73.

  76. 76.

    Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. Gut . 1987;28:1510–3.

  77. 77.

    Lacy BE, Weiser K, De Lee R. The treatment of irritable bowel syndrome. Therap Adv Gastroenterol. 2009;2:221–38. https://doi.org/10.1177/1756283X09104794

Download references

Author information

Affiliations

  1. Department of Gastroenterology and Hepatology, Digestive Diseases and Surgical Institute, Cleveland Clinic, Cleveland, OH, USA

    • Afrin Kamal MD
  2. Department of Gastroenterology and Hepatology, Digestive Diseases Center, Cedars-Sinai, Los Angeles, CA, USA

    • Mark Pimentel MD, FRCP(C)

Authors

  1. Search for Afrin Kamal MD in:

  2. Search for Mark Pimentel MD, FRCP(C) in:

Guarantor of the article

Mark Pimentel.

Specific author contributions

AK drafted and revised the manuscript. MP reviewed and revised the manuscript. Both AK and MP have approved the final draft submitted.

Financial support

None.

Potential competing interests

Cedars-Sinai has licensing agreements with Valeant Pharmaceuticals International Inc., Commonwealth Laboratories Inc., and Synthetic Biologics Inc. Mark Pimentel is a consultant for Valeant Pharmaceuticals, Commonwealth Laboratories Inc., Synthetic Biologics Inc., Micropharma Inc., and Naia Pharmaceuticals and is on the advisory boards for Valeant Pharmaceuticals and Commonwealth Laboratories. The remaining authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Mark Pimentel MD, FRCP(C).

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/s41395-018-0241-2